A vascular-associated fibroblastic cell controls pancreatic islet immunity

Autor/innen

  • Don Clarke
  • Anne Costanzo
  • Siddhartha Sharma
  • Lisa Kain
  • Kelley W. Moremen
  • Jeremy Pettus
  • Alain Domissy
  • Peng Wu
  • Kim-Vy Nguyen-Ngoc
  • Denise Berti
  • Steven C. George
  • Christopher C.W. Hughes
  • Maike Sander
  • Luc Teyton

Journal

  • Cell Reports

Quellenangabe

  • Cell Rep 44 (9): 116189

Zusammenfassung

  • The immune protection of pancreatic β cells has three layers: anatomical, with their distribution in 1 million islets; central, with the thymic deletion of β cell-specific T cells; and peripheral, with inhibitory cellular networks. The failure of the latter leads to most spontaneous type 1 diabetes and all diabetes induced by checkpoint inhibitor therapy. Because CD4 T cells initiate disease, major histocompatibility complex (MHC) class II-expressing cells are central to the onset. In non-diabetic mouse and human islets, two such cells were detected outside of the islet boundaries near the efferent post-capillary venules: one related to the vasculature and a fibroblast referred to as a "vascular-associated fibroblast" (VAF). Functionally, primary VAFs spontaneously presented islet antigens to CD4 T cells and expressed high levels of inhibitory B7 receptors and no costimulatory receptors. VAFs induced anergy in primary pre-activated anti-islet CD4 T cells. VAFs are likely important to protect the endocrine pancreas from autoimmunity.


DOI

doi:10.1016/j.celrep.2025.116189